2019 CYIR Finalized
52 follow up overall survival (OS) was reported at 66.3% vs. 55.6% (p=0.005) in favour of durvalumab. Median OS was not reached in the immunotherapy arm [(95% CI=34.7-NR) vs. 28.7m (95% CI=22.9-NR), HR=0.68, p=0.0025)]. Median PFS was 17.2m vs. 5.6m (HR=0.51) in favour of durvalum- ab. Grade 3 or more toxicity was marginally higher in the immunotherapy arm (30.5% vs. 26.1%). Comments 1. This is a practice changing study. 2. Median OS has still not been reached in the immunotherapy arm as the survival arm begins to plateau. 3. All pre-specified subgroups derived benefit. 4. New sites of disease were less frequent in the durvalumab arm, most common being lung. 5. Median time to death / distant metastases was longer in the durvalumab arm (28.3m v 16.2m, HR 0.53). PEMBROLIZUMAB PLUS CHEMOTHERAPY IN METASTATIC NON–SMALL-CELL LUNG CANCER, KEYNOTE 189 Gandhi L, Rodriguez-Abreu D, Gadgeel S et al. Pembrolizumab plus Chemotherapy in Metastatic Non– Small-Cell Lung Cancer. N Engl J Med 2018; 378(22): 2078-2092 Summary In treatment-naïve patients with advanced (stage IIIB/ IV) non-squamous NSCLC, no known sensitizing EGFR/ ALK alterations have been shown to benefit from combi- nation immune checkpoint blockade and chemotherapy. This multinational, randomized clinical study recruited 616 patients to 4 cycles of pemetrexed + platinum followed by either pembrolizumab (200mg, every 3 weeks) or placebo and maintenance pemetrexed. Crossover was permitted to the immunotherapy arm in the those who progressed. 12 month survival was superior in the pembrolizumab arm; 69.2% vs. 49.4% (HR=0.49, p<0.001). Grade 3 or greater adverse events were similar in both arms; 67.2% v 65.8% respectively. Benefit was seen in all levels of PD-L1 expression, with the greatest survival seen at 50% or more expression. Comments 1. This is a change of practice study combining anti-PD1 therapy with chemotherapy. 2. A trial comparing frontline pembrolizumab monotherapy with combination is needed. 3. Survival curves begin to plateau at time of analysis. 4. Grade 3 of greater toxicity profile similar between the groups. 5. Intracranial response not measured as patients excluded with cerebral metastases. BRIGATINIB VERSUS CRIZOTINIB IN ALK-POSITIVE NON SMALL CELL LUNG CANCER, ALTA-1L Camidge DR, Kim HR, Ahn MJ et al. Brigatinib versus crizotinib in ALK-positive non small cell lung cancer. N Engl J Med 2018: 379(21): 2027-2039 Summary Targeted therapy against the fusion product of the EML4- ALK translocation has revolutionized treatment and prog- nosis in this small group of lung cancer patients. Further generations of ALK inhibitors, proven beneficial in crizo- tinib resistant disease, are demonstrating superior survival advantages in the frontline setting such as in this phase III clinical trial comparing the next generation ALK inhibitor, brigatinib, with crizotinib in patients with NSCLC (stage IIIB/IV) harbouring translocations in ALK. 275 patients with ALK translocated disease were randomized (1:1) to either brigatinib (180mg od) or crizotinib (250mg bd). Crossover into the brigatinib arm was permitted at progression. At the first interim analysis, 12 month progression-free survival (PFS) was superior in the brigatinib arm (67% vs. 43%, HR=0.49, P<0.001). Benefits were also seen in overall response rate (71% vs. 60%) including intracranial response (78% vs. 29%). Comments 1. Patient characteristics consistent with previous studies. 2. 27% of patients received chemotherapy prior to study partici- pation, however all were ALK targeted TKI naïve. 3. HR of 0.20 in patients with baseline brain metastases. 4. 12 month duration of response superior in brigatinib arm (75 v 41%). 5. 29% of the total cohort had brain metastases. FIRST-LINE ATEZOLIZUMAB PLUS CHEMOTHERAPY IN EXTENSIVE-STAGE SMALL-CELL LUNG CANCER Horn L, Mansfield AS, Szczesna A et al. First-Line Atezolizumab plus Chemotherapy in Extensive-Stage Small-Cell Lung Cancer. N Engl J Med 2018: 379(23):2220- 2229 Summary Standard of care in SCLC constitutes chemotherapy offering excellent initial response rates but inevitable progression of the disease in many. Anti PD-L1 therapy has been tested across several tumour types with success. This randomized phase III study recruited patients to receive etoposide and carboplatin with either placebo (n=202) or atezolizumab (n=201) until disease progression or intolerable toxicity. Median overall survival was reported to be 12.3m vs. 10.3m in favour of atezolizumab (HR=0.70, p=0.007). PFS was also superior (5.2m vs. 4.3m, HR=0.77, p=0.02). Similar toxicity profile LUNG CANCER
Made with FlippingBook
RkJQdWJsaXNoZXIy MTM1ODMw